These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38935360)

  • 41. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells.
    Roux-Lombard P; Modoux C; Vischer T; Grassi J; Dayer JM
    J Rheumatol; 1992 Apr; 19(4):517-23. PubMed ID: 1593570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
    Dinarello CA; Simon A; van der Meer JW
    Nat Rev Drug Discov; 2012 Aug; 11(8):633-52. PubMed ID: 22850787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthetic C-terminal peptide of IL-1 functions as a binding domain as well as an antagonist for the IL-1 receptor.
    Palaszynski EW
    Biochem Biophys Res Commun; 1987 Aug; 147(1):204-11. PubMed ID: 2958006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anakinra and its rapidly expanding role in management of nonarthritic systemic disorders.
    Kapoor S
    J Rheumatol; 2009 Feb; 36(2):446; author reply 447. PubMed ID: 19208574
    [No Abstract]   [Full Text] [Related]  

  • 45. Interleukin-1 inhibitors.
    Seckinger P; Dayer JM
    Ann Inst Pasteur Immunol; 1987; 138(3):486-8. PubMed ID: 2958020
    [No Abstract]   [Full Text] [Related]  

  • 46. Inhibition of interleukin-1beta (IL-1beta) production in human cells by ribozymes against IL-1beta and IL-1beta converting enzyme (ICE).
    Leavitt MC; Yu G; Zhou C; Barber JR
    Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):409-14. PubMed ID: 11198924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Finding a place for interleukin-1 inhibitors in the treatment of rheumatologic diseases.
    Finch D; Sleeman M
    Curr Pharm Des; 2015; 21(17):2198-205. PubMed ID: 25760298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of a specific 20- to 25-kD interleukin-1 inhibitor from cultured human lung macrophages.
    Galve-de Rochemonteix B; Nicod LP; Junod AF; Dayer JM
    Am J Respir Cell Mol Biol; 1990 Oct; 3(4):355-61. PubMed ID: 2144978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
    Perrier S; Darakhshan F; Hajduch E
    FEBS Lett; 2006 Nov; 580(27):6289-94. PubMed ID: 17097645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis.
    Ikonomidis I; Tzortzis S; Andreadou I; Paraskevaidis I; Katseli C; Katsimbri P; Pavlidis G; Parissis J; Kremastinos D; Anastasiou-Nana M; Lekakis J
    Circ Cardiovasc Imaging; 2014 Jul; 7(4):619-28. PubMed ID: 24782115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interleukin-1 antagonists.
    Dinarello CA
    J Interferon Res; 1994 Oct; 14(5):307. PubMed ID: 7861041
    [No Abstract]   [Full Text] [Related]  

  • 52. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention.
    Braddock M; Quinn A
    Nat Rev Drug Discov; 2004 Apr; 3(4):330-9. PubMed ID: 15060528
    [No Abstract]   [Full Text] [Related]  

  • 53. 'Prototypical' proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting.
    Musella A; Fresegna D; Rizzo FR; Gentile A; De Vito F; Caioli S; Guadalupi L; Bruno A; Dolcetti E; Buttari F; Bullitta S; Vanni V; Centonze D; Mandolesi G
    Expert Opin Ther Targets; 2020 Jan; 24(1):37-46. PubMed ID: 31899994
    [No Abstract]   [Full Text] [Related]  

  • 54. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
    Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
    Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Options for blocking interleukin-1 in patients with rheumatoid arthritis.
    Boissier MC; Bessis N; Falgarone G
    Joint Bone Spine; 2002 Jun; 69(4):351-4. PubMed ID: 12184428
    [No Abstract]   [Full Text] [Related]  

  • 56. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor.
    Granowitz EV; Clark BD; Mancilla J; Dinarello CA
    J Biol Chem; 1991 Aug; 266(22):14147-50. PubMed ID: 1830582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases.
    Palomo J; Dietrich D; Martin P; Palmer G; Gabay C
    Cytokine; 2015 Nov; 76(1):25-37. PubMed ID: 26185894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The mechanism and specificity of IL-1 inhibitory factor released from human alveolar macrophages].
    Takeuchi M; Aung H; Nagai S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1409-16. PubMed ID: 1434212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Xanthelasma palpebrarum responding to interleukin-1 blockade.
    Szturz P; Adam Z; Rehák Z; Koukalová R
    Intern Med J; 2014 Jun; 44(6):617-8. PubMed ID: 24946821
    [No Abstract]   [Full Text] [Related]  

  • 60. Human interleukin 1.
    Krakauer T
    Crit Rev Immunol; 1986; 6(3):213-44. PubMed ID: 2942337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.